Tanezumab Overview

Introduction of Tanezumab

Tanezumab (RN624) is a recombinant humanized anti- nerve growth factor (NGF) monoclonal antibody (IgG2 type) that works by inhibiting the binding of NGF to its receptors. It was developed by Pfizer as a treatment for pain.

Mechanism of Action of Tanezumab

Tanezumab’s primary effect is to inhibit the interaction between NGF and its high affinity receptor TrKA and low-affinity receptor p75. The TrKA is a tyrosine kinase receptor, while p75 is a specific receptor for the NGF ligand. Peripheral nociceptive fibers and nociceptors, rich in p75 and TrKA receptors, are dependent upon NGF for both genesis and ongoing function. Nociceptor development is dependent upon NGF. Pain processing is heavily reliant on the presence of NGF, particularly in “C” fibers, which have been implicated in both acute and chronic pain.

Fig.1 Mechanism of action of tanezumab.

Clinical Projects of Tanezumab*

What We Provide

Therapeutic Antibody

Tanezumab

We provide high-quality Tanezumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Tanezumab

For research use only. Not intended for any clinical use.